| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
We assessed the utility of precise tag sequencing that eliminates PCR and sequence error-derived noises. Digital PCR was conducted for 45 patients with KRAS mutation in the EUS-FNA samples. Tag sequence of cfDNA was performed for patients with >2% allele frequency in KRAS by digital PCR. Tag sequence could detect mutations in KRAS (44%) and TP53 (28%) as well as copy number alterations in CCND2 (1 case), FGFR1 (1 case), and MYC (2 cases). Tag sequence for cfDNA and EUS-FNA samples was possible and could be informative for the clinical implication and therapeutic decisions. These results would lead to further development toward the improvement of prognosis of pancreatic cancer.
|
